Articles tagged with: IMGN901
News»

Results from an ongoing Phase 1 study demonstrate that lorvotuzumab mertansine in combination with Revlimid and dexamethasone is effective as a therapy for relapsed and refractory myeloma patients.
The updated trial results were presented by Dr. Jesus Berdeja from the Sarah Cannon Research Institute in Nashville, Tennessee, the American Society of Hematology (ASH) annual meeting in Atlanta last month.
Ten patients are currently continuing with the clinical trial. According to Dr. Berdeja, these interim results support the continued evaluation of the combination in relapsed and refractory myeloma patients. "This was a fairly …
News»

This year’s American Society of Hematology (ASH) meeting, which is taking place in Atlanta, came to a close earlier today. However, yesterday, the third day of the meeting, was packed with myeloma-related presentations.
Given the number of myeloma presentations made yesterday, The Beacon will summarize the four most important of yesterday’s oral presentation sessions as well as a number of the most important poster presentations in updates such as this one. Summaries of the first three key oral presentation sessions were published yesterday and earlier today. This update covers presentations from the …
News»

During the upcoming annual meeting of the American Society of Hematology (ASH), which will be held December 8 through 11 in Atlanta, results will be presented from clinical trials involving a number of potential new drugs under development for the treatment of multiple myeloma.
In particular, results for newer, lesser known agents that are in the early stages of clinical development will take center stage. These agents include ARRY-520 (filanesib), BHQ880, circularly permuted TRAIL, daratumumab, dinaciclib, lorvotuzumab mertansine, oprozomib, and tabalumab.
According to the recently …
News»

Treatment strategies that combine Revlimid with newer types of anti-tumor agents may be effective for relapsed and refractory multiple myeloma, according to myeloma experts who reviewed results from studies of these new combinations.
Refractory and relapsed multiple myeloma is notoriously difficult to treat. For every remission period that is achieved, relapse typically arises sooner and with greater resistance to previously used therapies. These patients have limited options for therapy.
In examining trials that tested new therapies in combination with Revlimid (lenalidomide), the authors of the review hoped to find the potential …
News»

Results of an ongoing Phase 1 clinical trial indicate that the anti-cancer drug lorvotuzumab mertansine in combination with Revlimid-dexamethasone is active in relapsed/refractory multiple myeloma patients.
“There is encouraging activity observed at all dose levels,” said Dr. Jesus Berdeja from the Sarah Cannon Research Institute in Nashville, Tennessee, who presented these findings at the 47th Annual Meeting of the American Society of Clinical Oncology (ASCO) on Sunday.
In a summary talk about potential new myeloma treatments, Dr. Nikhil Munshi from the Dana-Farber Cancer Institute said that he was encouraged by these first …
News»

Yesterday was the third day of the American Society of Clinical Oncology (ASCO) 2011 annual meeting in Chicago, and it was especially packed with presentations related to multiple myeloma.
There was a morning session where a total of eight research abstracts were presented and discussed. Then, late in the afternoon, there was an education session focused on multiple myeloma, with several different presentations.
The presentations during the morning session were on three different topics: Revlimid (lenalidomide) and its potential link to secondary cancer; myeloma bone disease; and new drugs being developed as potential …
News»

The 47th annual meeting of the American Society of Clinical Oncology (ASCO) will take place Friday, June 3, through Tuesday, June 7, in Chicago.
More than 30,000 clinical specialists from all over the world are expected to attend the five-day meeting to discuss the current research in cancer treatment and care. This year’s meeting will primarily focus on the theme of “Patients, Pathways, Progress.”
The meeting will include many presentations and seminars focused specifically on multiple myeloma. The ASCO website currently lists over 40 myeloma-based abstracts.
The Myeloma Beacon will be …